Advertisement




Related Videos

Breast Cancer

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor–positive early breast cancer.”

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.

Breast Cancer

Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract PD2-1, “The effect on overall and disease-free survival by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40.”

Breast Cancer

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic breast cancer: Part I results.”

Breast Cancer

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.

Advertisement

Advertisement



Advertisement